{"disease":{"id":"bipolar-affective-disorder-current-episode-depression","name":"Bipolar affective disorder, current episode depression","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"fluoxetine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"lurasidone","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"doxepin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prozac","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"fluoxetine","guideline_body":"FDA label","recommendation":"Fluoxetine and olanzapine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}